Type 1 Diabetes Mellitis
11
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (11)
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise
Diathermy On Diabetes Glucose Monitoring Effectiveness
Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility
Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
Metabolic Control and Glycemic Variability in Type 1 Diabetes and Celiac Disease
Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes
Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)